Conference Correspondent

Daratumumab plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a 4-Arm Phase 1b Study

Conference Correspondent 

Chari and colleagues presented results of a 4-arm, open-label, multicenter, phase 1b study that evaluated the safety and efficacy of the anti-CD38 monoclonal antibody daratumumab in combination with pomalidomide and dexamethasone in patients with relapsed and refractory multiple myeloma.1 The study population (n = 98) had received a median of 4.0 (2-13) prior therapies; 98% of patients were refractory to bortezomib, 32% to carfilzomib, 89% to lenalidomide, and 67% to both a proteasome inhibitor and immunomodulatory drug. Of the 38 patients who discontinued study treatment, 19 (50%) were due to progressive disease and 8 (21%) were due to adverse events (AEs). Daratumumab-specific infusion-related reactions occurred in 52 patients, and included chills (14%), cough (11%), and dyspnea (11%). Grade 3/4 AEs were mostly hematologic, including neutropenia, anemia, leukopenia, and thrombocytopenia; nonhematologic grade 3/4 AEs included dyspnea, hypertension, and fatigue. Seventeen deaths were reported. In the 75 patients who had >1 postbaseline assessments, an overall response rate (ORR) of 53% was achieved, including 4 stringent complete responses, 3 complete responses, 25 very good partial responses, and 21 partial responses. Patients also achieved greater depth of response over time. In the cohort of patients with double-refractory disease, an ORR of 67% was achieved. The 6-month progression-free survival was 66%. Based on these results, the authors concluded that the addition of daratumumab to Pom/Dex resulted in high response rates, greater depth of responses, without unexpected or exacerbating known toxicities.

  1. Chari A, et al. ASH 2015. Abstract 508.

Related Items


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: